Want to see KR:003060 full AI Analyst Report?
Aprogen Biologics (003060) Financial Statements
Aprogen Biologics Financial Overview
Aprogen Biologics's market cap is currently $40.05B. The company's EPS TTM is $-5874.57; its P/E ratio is -0.23; Aprogen Biologics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 73.23B | $ 67.38B | $ 87.36B | $ 65.19B | $ 56.48B |
| Gross Profit | $ -28.42B | $ -7.58B | $ -12.05B | $ 27.29B | $ 25.44B |
| Operating Income | $ -122.89B | $ -52.82B | $ -69.95B | $ 12.81B | $ 10.49B |
| EBITDA | $ -103.70B | $ -51.33B | $ -88.32B | $ 17.56B | $ 11.93B |
| Net Income | $ -170.33B | $ -104.98B | $ -118.27B | $ 5.58B | $ 8.10B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 51.02B | $ 38.32B | $ 10.05B | $ 99.07B | $ 124.94B |
| Total Assets | $ 586.99B | $ 590.98B | $ 589.40B | $ 676.10B | $ 614.62B |
| Total Debt | $ 225.32B | $ 154.02B | $ 181.00B | $ 134.74B | $ 2.48B |
| Net Debt | $ 200.93B | $ 141.71B | $ 170.94B | $ 111.13B | $ -32.59B |
| Total Liabilities | $ 305.95B | $ 212.29B | $ 220.71B | $ 173.73B | $ 17.44B |
| Stockholders' Equity | $ 207.76B | $ 378.49B | $ 368.69B | $ 421.72B | $ 507.94B |
| Cash Flow | |||||
| Free Cash Flow | $ -47.86B | $ -46.45B | $ -62.05B | $ 24.18B | $ -7.67B |
| Operating Cash Flow | $ -38.23B | $ -31.00B | $ -33.65B | $ 25.73B | $ -6.23B |
| Investing Cash Flow | $ -85.12B | $ -51.72B | $ -95.21B | $ -53.00B | $ -23.16B |
| Financing Cash Flow | $ 135.14B | $ 84.97B | $ 115.29B | $ 15.78B | $ -350.26M |
Currency in KRW